Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of QLS32015 combination therapy in relapsed or refractory multiple myeloma
CTR20252454Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QLS32015 in multiple myeloma (MM), sponsored by Qilu Pharmaceutical. Started Sep 2025; status: active.
02
Drugs
QLS32015
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20252454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252454.